Introduction
A new piece of legislation (Regulation [EC] No. 1901/2006 as amended) namely the "Paediatric Regulation" governing the development and authorisation of medicines for use in children 0 to less than 18 years was introduced in the European Union in January 2007.
The Paediatric Regulation [1] also brings in many new tasks and responsibilities for the European Medicines Agency (EMA), chief of which is the creation and operation of a Paediatric Committee (PDCO) within the Agency to provide objective scientific opinions on any development plan for medicines for use in children.
Since the Paediatric Regulation came into force in January 2007, the regulatory environment for paediatric medicines has dramatically changed. The Regulation requires pharmaceutical companies to consider the needs of the paediatric population during the development of their medicinal product. The Paediatric Regulation requires companies to submit a Paediatric Investigation Plan (PIP; for further description of EMA terms see Table 2 ) for their product, which is evaluated by the PDCO in 60 to 120 days. There is a possible clock stop at day 60 to allow companies to respond to requests for modification of the plan. PDCO opinions on PIPs and waivers are transformed into binding European Medicines Agency decisions [2] . The PIP is submitted for review by the PDCO no later than the completion of the relevant human pharmacokinetic studies in adults. A waiver can be granted for a specific product, an indication or a class of products based on of the following three grounds:
1. That the specific medicinal product or class of medicinal products is likely to be ineffective or unsafe in part or all of the paediatric population 2. That the disease or condition for which the specific medicinal product or class is intended occurs only in adult populations 3. That the specific medicinal product does not represent a significant therapeutic benefit over existing treatments For products already authorised, including active substances protected by a supplementary protection certificate, or by a patent eligible for a supplementary protection certificate, Article 8 of the Regulation applies. In these circumstances, companies have the obligation to submit the results of an agreed PIP covering all existing and new indications, new routes of administration or new formulations, unless a waiver has been granted by the PDCO.
For medicinal products not yet authorised Article 7 of the Regulation applies, and companies have the obligation to submit results of an agreed PIP, unless a waiver has been granted by the PDCO. Deferrals for the completion of trials (not for the submission of PIPs) can also be granted by the PDCO, to protect the safety of children until additional safety data in adults are available.
For off-patent products already available on the market for adults only, without information and/or a formulation appropriate for children of all ages Article 30 can apply, where companies submit a PIP on a voluntary basis leading to a Paediatric Use Marketing Authorisation (PUMA). The PIP must be agreed and covers paediatric indications and formulation. An overview of Articles 7, 8 and 30 can be seen in Table 1 .
Ethical concerns that too many vulnerable children are recruited into clinical trials must be balanced against limiting the number of off-label prescribing and obtaining age-appropriate information on paediatric use. Within the context of a clinical trial safety monitoring can be done rigorously, and any safety concerns noted early on, minimised or prevented.
The PDCO is not responsible for marketing-authorisation applications for medicinal products for paediatric use. This remains fully within the remit of the Committee for Medicinal Products for Human Use (CHMP) [3] . However, the CHMP or any other competent authority may request the PDCO to prepare an opinion on the quality, safety and efficacy of a medicinal product for use in the paediatric population if these data have been generated in accordance with an agreed paediatric investigation plan.
A review of all the PIPs submitted with a Decision reached between September 2007 and March 2010 was conducted to examine the impact of the Regulation on the therapeutic field of Pain, not only in terms of numbers of PIPs received, but also in relation to the number and types of clinical trials to be conducted, and the number of children to be recruited. It also records scientific data, while streamlining work procedures by producing pre-filled documents and interacting directly with a secure e-mail system to send messages and documents to external addressees (including applicants).
Materials and methods

Utilising
The key word "pain" was used in search fields "condition/indication" and therapeutic area as the main parameter to identify the PIPs of interest. The Pain PIPs identified were then categorised according to type of product (Table 2) : Article 8 for products already authorised, Article 7 for medicinal products not yet authorised and for off-patent products already available on the market for adults only, Article 30.
The key words "diabetes", "human immunodeficiency virus (HIV)" and "infectious diseases" were used in the The CHMP's scientific conclusions on issues related to medicinal products, e.g. whether the data submitted allow to conclude that there is an overall positive benefit/risk of a new product in a proposed indication and whether the product should be placed on the market. Any application for scientific advice following the initial application on the same area/condition. For example, the initial advice can be on the pharmacokinetics and the exploratory phase II trial, and later the pivotal Phase III trial could be the subject of follow-up advice.
Informed consent applications
According to Article 10c of Directive 2001/83/EC as amended, following the granting of a marketing authorisation, the authorisation holder may allow use to be made of the pharmaceutical, non-clinical and clinical documentation contained in the dossier of the medicinal product for the purpose of examining subsequent applications relating to other medicinal products possessing the same qualitative and quantitative composition in terms of active substances and the same pharmaceutical form. http://www.ema.europa.eu/htms/human/presub/q03.htm MAA Marketing Authorisation Application: across all European markets, plus Australia, New Zealand, South Africa and Israel (exceptions amongst major markets include USA, Canada, China and Japan), the Marketing Authorisation Application (MAA) is a common document used as the basis for a marketing application (an application for approval to market the product based on a full review of all quality, safety, and efficacy data, including clinical study reports). In the USA, the New Drug Application (NDA) is the MAA equivalent. In Canada, the New Drug Submission (NDS) is the MAA equivalent. http://www.ema.europa.eu/index/indexh1.htm Medicinal product A finished dosage form, for example, tablet, capsule, solution, etc., that contains an active ingredient generally, but not necessarily, in association with inactive ingredients. The term also includes a finished dosage form that does not contain an active ingredient but is intended to be used as a placebo. Multiple applications MAAs, where the applicants wish to obtain, either simultaneously or successively, more than one Marketing Authorisation for a specific medicinal product, under different invented names. http://www.ema.europa.eu/htms/ human/presub/q09.htm OD Orphan Drug: a drug for the treatment of a rare, serious disease (defined in the EU as a condition that affects not more than 5 in 10,000 persons in the Community, and in the US as a condition affecting fewer than 200,000 people) or for a disease not likely to generate sufficient profit to justify research and development costs. http://www.ema.europa. eu/htms/human/orphans/intro.htm PDCO The main responsibility of the Paediatric Committee (PDCO) is to assess the content of paediatric investigation plans and adopt opinions on them in accordance with Regulation (EC) 1901/2006 as amended. This includes the assessment of applications for a full or partial waiver and assessment of applications for deferrals http://www.ema. europa.eu/htms/general/contacts/PDCO/PDCO.html search fields "condition/indication" and therapeutic area as the main parameter to identify PIPs to be compared in terms of numbers of pharmaceutical drugs that have been submitted with the therapeutic area of pain.
Results
Seventeen submissions were made to the Paediatric Committee (PDCO) for assessment. Three were withdrawn by the applicants during the procedure; the reasons for withdrawal were not communicated to the European Medicines Agency and PDCO. Twelve submissions were for Article 7 and from a known class, with only one of the submissions being a product with a new mechanism of action. The 13th submission was for Article 8 and the 14th submission was a Paediatric Use Marketing Authorisation request, which was also a well-known product widely used for other indications.
Seven out of the 12 Article 7 submissions were for fixed dose combinations, one of which included development in the adolescent age group, while the other was an application for a full waiver. The PDCO did not consider that they offered significant therapeutic benefit to children as a fixed combination. Although the effect of the substances on their own was known, the effect of the combination was unknown and would have required studies. However, the PDCO was of the opinion that fixed combinations were not appropriate in this case as they did not allow flexibility in the dosage according to age and weight. Therefor, waivers for paediatric development were granted for all age groups for these fixed combinations.
An eighth product was also a request for a waiver in all age groups, based on the grounds that the medicinal product did not represent a significant therapeutic benefit over existing available products. This submission was for an old product well known and widely used, but with a new formulation for intravenous use. In this instance, the PDCO did not agree that the product lacked the potential to meet the current needs; however, they had significant concerns about the content of the formulation for this product and about the lack of clinical data for prescribing in the neonatal age group. Discussions with the company regarding these concerns led to the development of a clinical trial designed to specifically investigate these key safety concerns.
One of the Article 7 submissions resulted in a negative opinion; the grounds for refusal cannot be communicated for legal reasons.
Finally, the last three PIP submissions under Article 7 were for the same active substance, but included both acute and chronic pain indications, with immediate and prolonged release formulations. The initial application included a request for a partial waiver for the 0-to less than 24-month age group. Following extensive discussion with the applicant, the PDCO agreed on PIPs for all the paediatric age groups, in both indications, but utilising modelling and simulation of pharmacokinetics in children less than 2 years of age.
The last PIP under Article 7 was for acute pain. The initial submission included a request for a partial waiver for the 0-to less than 24-month age group. Following discussion with the applicant, the PDCO agreed on PIPs for children aged 6 years to under 18 years and a partial waiver in children from birth to less than 6 years of age. The partial waiver was granted based on the grounds that the product does not represent a significant benefit over existing treatments.
The Article 8 PIP submission was refused by the PDCO. The PDCO had concerns that the proposed measures and timelines were not appropriate to generate necessary data to determine the conditions in which the medicinal product may be used to treat the paediatric population or subsets thereof, or to adapt a paediatric formulation. The PDCO also considered that the product would not bring significant therapeutic benefit. A product-specific waiver was granted on the PDCO's own motion on the grounds that the specific medicinal product was likely to be ineffective or unsafe in the whole paediatric population.
Another product submitted a request for a waiver for children older than 2 years because the expected lack of efficacy in this age group and lack of significant therapeutic benefit. The PDCO was in agreement with the data presented by the applicant and therefore a Partial Waiver for children over 2 years of age was granted.
Overall, Opinions as issued by the PDCO following discussion with the applicant resulted in the agreement of 13 clinical trials, with a total of at least 1,282 children to be recruited across five different products. The number of studies per product ranged from one to six.
For two of the products, the PDCO agreed to studies across the full paediatric age range (from birth to 18 years), starting with the older children (6 to less than 18 years) and proceeding in a staggered stepwise manner to the younger children (2 to less than 6 years followed by the under 2 years age group). This staggered approach was adopted to maximise the safety of the children.
Following extensive discussion between the PDCO and the company, efficacy did not need to be demonstrated in a blinded fashion in two clinical trials, on the grounds that data would be generated in other studies with the same compound, albeit in a different pain model. Four studies for one product were placebo-controlled, as there was no pharmacological alternative currently used or available in clinical practice. However, the study protocols included clear guidance for "rescue treatment". Five other studies across three different products were activecontrolled; however, only two were blinded due to complexities in achieving this. Four of the studies were for pharmacokinetics only, and one of the studies was a modelling and simulation of pharmacokinetics.
Neonates were included in four agreed PIPs. Only one applicant had included neonates in their original PIP submission, and their inclusion in the other three PIPs was only after evaluation by the PDCO, and subsequent discussions with the companies. Preterm neonates were included in two agreed PIPs, again following PDCO evaluation, with the primary aim of identifying pharmacokinetics data in three PIPs. Population pharmacokinetics, microassay and sparse sampling were agreed in all four PIPs, limiting the individual burden for each infant. This is an important step forward given the lack of current available data for many drugs in the neonatal age group, while causing minimal pain and distress.
Three out of the five proposed PIPs were non-opioids intended for mild to moderate pain. One PIP was specifically for procedural pain and the last PIP was for acute pain. Only the new product had the potential to work as Step III analgesia, as defined by the World Health Organization three-step analgesic ladder [6] .
Formulations
The development of intravenous and age-appropriate oral formulation, in immediate and prolonged release forms, has the potential to be of significant therapeutic benefit to the paediatric population.
Eleven of the 14 submissions included formulations for oral use, 2 of the 14 included intravenous formulation, 1 submission was for inhalation use and the last submission was for a nasal spray. Age-appropriate formulations were not adequately addressed in 7 of the original submissions. Following review by the PDCO 2 of the applicants agreed to develop an age-appropriate formulation. This would indicate that the legislation has been able to positively influence the development of age-appropriate formulations where they otherwise may not have been developed.
Discussion
Effective management of childhood pain is a high priority. There is now conclusive evidence that paediatric patients of all ages, including the extremely premature neonates [7] , are capable of experiencing pain as a result of tissue injuries, medical illnesses, therapeutic and diagnostic procedures, trauma and surgery. A range of medications is available to treat a variety of pain types [8] , but not all are suitable for all age subsets. There is increasing knowledge in the understanding of developmental neurobiology, developmental pharmacology and of the psychological needs of children in pain; however, a gap remains.
The paediatric population (birth to 18 years) in the European Union is close to 100 million, and up to 10% will undergo some type of surgical procedures every year, not to mention suffering other painful conditions. Paediatric patients experience pain in different clinical situations following trauma, during hospital stays and in pathological conditions treated by physicians outside the hospital, such as headache and acute abdominal pain, which are common during childhood. An epidemiological survey of 9,000 school children found that one third of 7-year-old children and half of 15-year-olds had headaches. In a survey carried out in school children in Germany (n=749) [9] , 83% of children and adolescents reported experiencing pain during the preceding 3 months. Many of these children, in all age groups, require analgesia.
Prior to the implementation of the Regulation, the Paediatric Working Party, a temporary working party of the Committee on Medicinal Products for Human Use (CHMP)-conducted an exercise between 2001 and 2007 to establish "Paediatric Needs" [10] . The lists of paediatric needs as adopted by the Working Party serves as a basis for the inventory of needs that is to be established and published by the Paediatric Committee in accordance with the Paediatric Regulation. This list is intended to guide the Committee when assessing PIPs.
Another list, the "Priority List of Off-patent Medicines" [11] has been set up to direct research on off-patent medicines, for which there is a high need in the paediatric population. With the availability of funding, provided through the European Union Framework Programmes, the aim is that more of these medicines will be developed for children and submitted for a Paediatric Use Marketing Authorisation. Conditions with higher therapeutic needs were initially identified as early as 2002-2003, mostly based on the severity of the disease; the paediatric groups affected (with special priority for the neonatal population); the non-availability of treatment alternatives; and the high prevalence of the disease in the paediatric population. For each condition, published therapeutic reviews of medicines used in children were analysed to identify off-label products of therapeutic interest and priorities for research. The list comprises a number of medicines relating to various therapeutic areas and is regularly updated.
Analgesia in the paediatric population was identified as an area with high therapeutic needs in the "Priority List" and in the "Paediatric Needs".
Pain management has one of the highest needs compared with other therapeutic areas, especially when considering the high incidence and prevalence of pain in the paediatric population across all conditions. When comparing the number of PIP submissions in pain with other therapeutic fields in the same time period, however, we note that the numbers of products being developed are small. In the same period, 21 PIPs were submitted in the therapeutic area of diabetes (12 still under review), and 12 submitted for the human immunodeficiency virus (9 still under review). The preva-lence and incidence of these indications compared with pain (5 still under review) are comparatively much lower, but are noted to be very active areas in terms of drug development.
Development in pain is low in comparison to the high incidence and despite the high therapeutic need identified in the priority list.
Conclusion
There is an apparent lack of innovative drugs being developed for pain, compared with some other therapeutic areas; however, this may not be a paediatric-only problem. Despite the Paediatric Regulation, the industry remains at liberty to study in any therapeutic area of their choice. This is an opportune time for clinicians, academia, learned societies and industry to collaborate for the discovery of new products, the generation of new data and the development of new formulations to ultimately benefit the needs of children and neonates in pain. The Paediatric Regulation serves to force industry to consider the needs of children in the development plans of their products, while the PDCO serves to ensure that only studies that offer significant value are agreed upon for the final Decisions.
